About human c esterase inhibitor
Plasma-derived C1 esterase inhibitor
Used for
- Prevents hereditary angioedema attacks in adults and children aged 6 years and older.
- Treats acute hereditary angioedema attacks in adults and children, where approved.
Usual adult dose
Prevention: 1,000 IU intravenously every 3–4 days. Acute attacks: 1,000 IU intravenously; a second dose may be given if needed.
Usual dose in children
Prevention, ages 6–11: 500 IU intravenously every 3–4 days. Acute attacks, ages 2–11: 500 IU if under 25 kg; 1,000 IU if 25 kg or more.
Common side effects
- Headache
- Nausea
- Rash
- Injection-site reactions
Important warnings
- Can cause serious allergic reactions, including anaphylaxis.
- Blood clots have occurred, especially with clotting risks or central venous access.
- Plasma-derived products carry a very small risk of transmitting infections.
- Acute-attack use may be off-label depending on country; follow local product labeling.
Pregnancy
Limited human data; use during pregnancy only when clearly needed and benefits outweigh potential risks.
Breastfeeding
It is unknown whether the medicine enters breast milk; consider benefits and potential risks with a clinician.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.